European Medicines Agency decision
P/0121/2013

of 3 May 2013
on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adalimumab (Humira), (EMEA-000366-PIPO4-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer
This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0121/2013

of 3 May 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adalimumab (Humira), (EMEA-000366-PIPO4-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by AbbVie Ltd. on 2 July 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 April 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for adalimumab (Humira), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for adalimumab (Humira), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for adalimumab (Humira), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This agreed PIP covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decisions P/102/2009 issued on 18 May 2009 and P/85/2010 issued on 1 June 2010, including subsequent modifications thereof.

**Article 5**

This decision is addressed to AbbVie Ltd., Abbott House, Vanwall Business Park, Vanwall Road, SL6 4XE – Maidenhead, United Kingdom.

Done at London, 3 May 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000366-PIP04-12

Scope of the application

Active substance(s):
Adalimumab

Invented name:
Humira

Condition(s):
Treatment of hidradenitis suppurativa

Authorised indication(s):
See Annex II

Pharmaceutical form(s):
Solution for injection

Route(s) of administration:
Subcutaneous use

Name/corporate name of the PIP applicant:
AbbVie Ltd.

Information about the authorised medicinal product:
See Annex II
Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd. submitted for agreement to the European Medicines Agency on 2 July 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 9 August 2012.

Supplementary information was provided by the applicant on 18 January 2013. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 12 April 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

1.1. Condition: Treatment of hidradenitis suppurativa

The waiver applies to:

- The paediatric population from birth to less than 12 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of hidradenitis suppurativa

2.1.1. Indication(s) targeted by the PIP

Treatment of hidradenitis suppurativa

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>
| Clinical        | 2                  | Measure 1
                 | PK-PD modelling exposure-response study               |
                 |                    | Measure 2
                 | Population PK modelling study.                       |
### 3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</th>
<th>Yes.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By December 2015.</td>
</tr>
<tr>
<td>Deferral for one or more measures contained in the paediatric investigation plan:</td>
<td>Yes.</td>
</tr>
</tbody>
</table>
Annex II

Information about the authorised medicinal product
**Condition(s) and authorised indication(s):**

1. **Rheumatoid arthritis**
   
   **Authorised indication(s):**
   
   Humira in combination with methotrexate, is indicated for:
   
   - the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying antirheumatic drugs including methotrexate has been inadequate;
   - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
   
   Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
   
   Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

2. **Polyarticular juvenile idiopathic arthritis**
   
   **Authorised indication(s):**
   
   Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Humira has not been studied in children aged less than 2 years.

3. **Axial spondyloarthritis**
   
   **Authorised indication(s):**
   
   Humira is indicated for the treatment of adults with severe active AS who have had an inadequate response to conventional therapy.
   
   Axial spondyloarthritis without radiographic evidence of AS
   
   Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C-reactive protein and / or magnetic resonance imaging, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs.

4. **Psoriatic arthritis**
   
   **Authorised indication(s):**
   
   Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.

5. **Psoriasis**
   
   **Authorised indication(s):**
Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultraviolet-A (PUVA).

6. Crohn's disease

Authorised indication(s):

Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

7. Paediatric Crohn's disease

Humira is indicated for the treatment of severe active Crohn’s disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

8. Ulcerative colitis

Authorised indication(s):

Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use